Patents by Inventor Randolph B. Deprince

Randolph B. Deprince has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130189219
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Application
    Filed: March 19, 2013
    Publication date: July 25, 2013
    Applicant: AMGEN INC.
    Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Publication number: 20120296072
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Application
    Filed: August 2, 2012
    Publication date: November 22, 2012
    Applicant: AMGEN INC.
    Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Patent number: 8258262
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: September 4, 2012
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Publication number: 20100310510
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Application
    Filed: December 16, 2009
    Publication date: December 9, 2010
    Applicant: AMGEN INC.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Patent number: 7662933
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: February 16, 2010
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Publication number: 20040181035
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Application
    Filed: March 26, 2001
    Publication date: September 16, 2004
    Applicant: Amgen, Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Patent number: 6506362
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: January 14, 2003
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Patent number: 6251864
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: June 26, 2001
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Patent number: 6121238
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: September 19, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Patent number: 5985265
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: November 16, 1999
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Patent number: 5824784
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Patent number: 5705693
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted arginine, lysine or ornithine residues, or derivatives thereof, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: January 6, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Randolph B. DePrince, Kevin L. Facchine, George S. Lewis, Jason G. Lewis, Kuei-Ying Lin, Mark D. Matteucci, Robert A. Mook, Jr., Richard W. Wagner
  • Patent number: 5008112
    Abstract: A device for the continuous administration of a diffusible agent having a relatively rapid rate of diffusion and a diffusible agent having a relatively show rate of diffusion comprises:a wall, formed at least in part by a porous membrane, which surrounds and defines a reservoir, the reservoir comprising:(a) a compartment which comprises the agent having the relatively slow rate of diffusion, wherein said compartment is in direct contact with the porous membrane part of the wall and(b) at least one compartment which comprises the agent having the relatively rapid rate of diffusion, wherein said compartment is not in direct contact with the porous membrane part of the wall and is separated from the compartment comprising the agent having the relatively slow rate of diffusion by a porous partition, such that when said device is exposed to said fluid medium, said agents will diffuse through the porous membrane part of said wall at a substantially steady rate for a prolonged period of time.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: April 16, 1991
    Assignee: International Minerals & Chem. Corporation
    Inventors: Randolph B. DePrince, Ravi Viswanathan
  • Patent number: 4917685
    Abstract: The present invention relates to a delivery device designed to be implanted in an animal and for the administration of a stabilized growth promoting formulation. This device has a wall formed at least in part by a porous membrane which surrounds and defines a reservoir. The reservoir contains a growth promoting hormone and a stabilizer. Examples of such stabilizers include certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts.
    Type: Grant
    Filed: May 16, 1986
    Date of Patent: April 17, 1990
    Assignee: International Minerals & Chem. Corp.
    Inventors: Ravi Viswanathan, Randolph B. DePrince
  • Patent number: 4898733
    Abstract: A device for the continuous administration of a beneficial agent to a living being at a substantially steady rate which comprises:(a) a body fluid-contacting layer which comprises a dispersion of an agent which is substantially soluble in the body fluid and a solid matrix material, said matrix material comprising a polymer which is substantially insoluble in said body fluid, and(b) a non-body fluid-contacting layer which comprises said beneficial agent,wherein said body fluid-contacting layer is compression molded to said non-body fluid contacting layer.
    Type: Grant
    Filed: November 4, 1985
    Date of Patent: February 6, 1990
    Assignee: International Minerals & Chemical Corp.
    Inventors: Randolph B. DePrince, Ravi Viswanathan
  • Patent number: 4765980
    Abstract: Porcine serum albumin stabilizes porcine growth hormone, and provided for sustained release of porcine growth hormone in implant devices for swine.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: August 23, 1988
    Assignee: International Minerals & Chemical Corp.
    Inventors: Randolph B. DePrince, Ravi Viswanathan
  • Patent number: 4663147
    Abstract: A device for the release of a diffusible solid in a fluid medium which comprises a disc which comprises a substantially uniform mixture of said diffusible solid and a polymer which is insoluble in and impermeable to said fluid medium and impermeable to said diffusible solid. The surfaces of said disc are coated with a polymer which is insoluble in and impermeable to said fluid medium and impermeable to said diffusible solid, with the exception of one or more apertures which extend through the disc and expose a portion of the mixture of diffusible solid and polymer to the fluid medium when the device is immersed therein. The aperture or apertures are placed in said disc such that as said fluid medium enters the disc through said aperture or apertures, the ratio of surfce area of diffusible solid exposed to the fluid medium to the length of the path through which the exposed solid must diffuse to exit the disc remains substantially constant.
    Type: Grant
    Filed: September 3, 1985
    Date of Patent: May 5, 1987
    Assignee: International Minerals & Chemical Corp.
    Inventor: Randolph B. DePrince